Self-Emulsifying Cannabinoid Formulation for Enhanced Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cannabinoids have low or variable bioavailability in some formulations due to their hydrophobic nature, necessitating improved drug delivery systems that enhance solubility and absorption for effective medical treatment.
Innovation Solution
A self-emulsifying pharmaceutical formulation comprising cannabinoids, non-ionic and ionic surfactants, partitioning solubilizers, clathrate solubilizers, and clarifying agents that form stable emulsions in aqueous media, increasing bioavailability and absorption through fine particle formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are formulated in conventional pharmaceutical formulations, then the formulation is simple to manufacture, but the bioavailability is low due to hydrophobic nature
Solution Approach 1:
The patent employs self-emulsifying drug delivery systems (SEDDS) that combine multiple components including lipids, surfactants, and co-surfactants to create a composite formulation. This composite structure enables the hydrophobic cannabinoids to form stable emulsions in aqueous environments, dramatically improving bioavailability while managing the inherent complexity through systematic formulation design
Solution Approach 2:
The invention utilizes parameter changes by controlling the physical state and composition ratios of formulation components. By adjusting the proportions of lipids, surfactants, and co-surfactants, and controlling emulsion droplet size parameters, the system achieves optimal bioavailability. The formulation transforms from a simple mixture to a complex self-emulsifying system through controlled parameter optimization
2Reliability
If lipid-based drug delivery systems are used to increase solubility, then bioavailability improves, but the formulation complexity increases
Solution Approach 1:
The patent implements self-service through self-emulsifying properties where the formulation automatically forms emulsions upon contact with aqueous environments in the body. The SEDDS components self-organize into micellar structures without requiring external emulsification equipment or complex processing, achieving enhanced solubility while minimizing manufacturing complexity
Solution Approach 2:
The invention exploits phase transitions by designing the formulation to transition from a liquid or semi-solid state to a fine emulsion state upon contact with gastrointestinal fluids. This phase change enables the hydrophobic cannabinoids to become dispersed in the aqueous environment, improving solubility and bioavailability through controlled physical transformation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly enhances the bioavailability and absorption of cannabinoids, allowing for effective treatment of various medical conditions through improved solubility and permeation across the intestinal membrane, providing a convenient and consumer-friendly delivery system.
Implementation Method 1
from about 1% to about 10% by weight of a non-ionic surfactant solubilizer, from about 0.1% to about 10% by weight of an ionic co-surfactant solubilizer
Implementation Method 2
self-emulsifying pharmaceutical formulations which optimizes cannabinoid or cannabinoid extract dissolution properties thereby enhancing bioavailability
Implementation Method 3
from about 0.001% to about 80% by weight of a first partitioning solubilizer, from about 0.001% to about 70% by weight of a second partitioning solubilizer
Implementation Method 4
from about 0.001% to about 30% by weight of a clathrate solubilizer
Data Source
AI summary
A composition is provided, including a self-emulsifying pharmaceutical formulation comprising from about 0.001% to about 40% by weight of a cannabinoid or a cannabinoid blend, from about 1% to about 10% by weight of a non-ionic surfactant solubilizer, from about 0.1% to about 10% by weight of an ionic co-surfactant solubilizer, from about 0.001% to about 80% by weight of a first partitioning solubilizer, from about 0.001% to about 70% by weight of a second partitioning solubilizer, from about 0.001% to about 30% by weight of a clathrate solubilizer, from about 0.01% to about 80% by weight of a clarifying solubilizer, and from about 0.001% to about 20% by weight of a sensate.